Navigation Links
Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin
Date:4/12/2011

EAST HANOVER, N.J., April 12, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval of Afinitor® (everolimus) tablets for the treatment of patients with advanced neuroendocrine tumors (NET) of pancreatic origin.

The recommendation was provided after presentation of data from the everolimus RADIANT (RAD001 In Advanced Neuroendocrine Tumors) trial program, the largest conducted in patients with advanced NET. The Phase III RADIANT-3 trial studied patients with advanced NET of pancreatic origin and showed a statistically significant improvement in progression-free survival with everolimus versus placebo(1).

The FDA can seek the advice of its advisory committees as it reviews and decides whether to approve treatments, although it is not obliged to follow the recommendation(4,5).

"We look forward to working with the FDA as it completes its review and we are encouraged by the advisory committee's recommendation to approve everolimus for patients with advanced pancreatic NET," said Herve Hoppenot, President, Novartis Oncology. "The study of everolimus in this patient population is an example of our commitment to identify targeted options for patients with critical unmet medical needs."

When pancreatic NET becomes advanced, meaning the cancer has spread to other parts of the body, it is considered aggressive and difficult to treat(6). Approximately 60% of pancreatic NET patients are diagnosed with advanced disease, and the five-year survival rate for these patients is 27%(3,7).

Everolimus targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism(2). Preclinical and clinical data have established the role of mTOR in the development and progression of several types of tumors, including advanced pancreatic NET, for which there are
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
2. Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
3. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
4. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
5. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
6. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
7. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
8. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
9. Novartis to Expand Global Research Headquarters in Cambridge, MA
10. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
11. Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if he wants ... engaged, he should address any hearing loss he may be ... Hearing Institute (BHI) is delivering to men around the ... which leads up to and includes Father,s Day. This year, ... 16. To help men address their hearing ...
(Date:5/23/2013)... , May 23, 2013  A recently published clinical ... Houston, Texas , demonstrates that 3D mammography ... cancer detection. The study, "Implementation of ... Study," was led by Stephen L. Rose ... of the American Journal of Roentgenology (AJR). ...
(Date:5/23/2013)... JERUSALEM , May 23, 2013  Hadasit Bio-Holdings ... portfolio of biotech companies, based on intellectual property ... Israel ,s foremost medical research center, ... Neurosciences Ltd., received significant funding from the Israeli ... Chief Scientist (OCS) to support product development and ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... YONKERS, N.Y.--(BUSINESS WIRE)--Jun 18, 2007 - Advanced ... biopharmaceutical,company, announced today that preliminary findings from ... treatment with AVR118,appears to have clinical activity ... incisions or dermatologic,dermabrasion., The Phase II open ...
... -- More than 70 abstracts highlight VELCADE efficacy ... care --, CAMBRIDGE, Mass., June 19, 2007 /PRNewswire-FirstCall/ ... the market leading therapy with unsurpassed single-agent,efficacy for ... featured at the upcoming International Myeloma,Workshop (IMW) in ...
Cached Medicine Technology:Advanced Viral Research Corp. Announces Positive Preliminary,Findings from Ongoing Phase II Dermatological Study 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 2Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 3Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 4Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 5Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 6Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 7Velcade (bortezomib) for Injection Survival Data in Front-Line,Multiple Myeloma Patients to be Featured at 11th International,Myeloma Workshop 8
(Date:5/23/2013)... 2013 Over the past decade, the ... which has affected the Medical Group Practice Management ... regular hours, more young physicians are opting out of ... groups,” says IBISWorld industry analyst Anna Son. In addition, ... number of older physicians are selling their practices and ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Whether working ... Operations Forces and law enforcement need an added layer ... Security Enhancer, Night VISER , is an effective ... motion sensing system to increase border and perimeter security. ... VISER have more than tripled over the past three ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Vegas ... is pleased to announce all new vacation packages ... in coming to Las Vegas for this patriotic ... it is thanks to VegasHotelEscapes.com's new special pricing ... to state that it guarantees the lowest prices ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Funeral Financials ... Memorial Day to the EOD Memorial Foundation ... be the greatest victims from the war. , ... originated in 1941 before the U.S. was even at ... Forces are identified with the Explosive Ordnance Disposal Badge. ...
(Date:5/23/2013)... -- A modified version of the polio virus ... research suggests. Scientists at Duke Cancer Institute ... uses an engineered form of the virus that ... cells. The therapy shows promise in the treatment ... tumor, they said. "These early results are ...
Breaking Medicine News(10 mins):Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Group Practice Management in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 2Health News:Lighting Up the Night: ARA Announces Record Sales of Its Night VISER System 3Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2
... Nov. 1 It is estimated more than two ... States, with about,one-in-six expected to get the disease at ... Society. Thankfully, new treatment,technologies are making surviving the disease ... and more Americans are too large to be treated,using ...
... Nov. 1 The Michael J. Fox,Foundation (MJFF) ... 2008 Target Validation effort. Under this annual program ... 2008 for projects designed to validate the,therapeutic potential ... possible pharmaceutical industry investment and clinical trials., ...
... discovered a novel mechanism to predict survival in older ... have significant implications for new treatment approaches. , For ... aromatase, an enzyme that naturally makes estrogen from another ... survival rates in women over 65 with Stage 1 ...
... do not necessarily have worse outcomes after liver transplantation. ... they fare just as well. These are the results ... Hepatology, a journal published by John Wiley & Sons ... of Liver Diseases (AASLD). The article is also available ...
... carbon nanotubes can be destroyed by non-invasive radio waves ... a research team led by scientists at The University ... University has shown in preclinical experiments. , In a ... journal Cancer, researchers show that the technique completely destroyed ...
... keeping good track of daily blood sugar levels, while ... -- Fewer American adults with diabetes are developing cardiovascular ... blood sugar levels, according to new U.S. government research ... and Prevention studies, published in the CDC,s weekly journal ...
Cached Medicine News:Health News:Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008 2Health News:Researchers discover new way to predict survival in older women with lung cancer 2Health News:Researchers discover new way to predict survival in older women with lung cancer 3Health News:No racial differences seen in outcomes after liver transplantation 2Health News:Radio waves fire up nanotubes embedded in tumors, destroying liver cancer 2Health News:Radio waves fire up nanotubes embedded in tumors, destroying liver cancer 3Health News:Adults With Diabetes Doing Better Prevention Job 2
The new Vascular ClearWay Irrigating PTFE Balloon Catheter is a revolutionary micro-porous PTFE balloon catheter designed for the removal of fresh, soft emboli and thrombi, and for intraluminal irrig...
... for every general surgery need. No matter ... the GO450/GO400 Omni-Flex™ General Retractor Systems give ... the best possible exposure in the simplest ... and the hinged extension arm, the GO450 ...
... gelatinase-associated lipocalin, lipocalin-2) is a new early ... renal failure with a >90% positive predictive ... urine, as early as 2 hours after ... diagnostic marker for acute renal failure. ,Quantitative ...
... Don't miss the sounds you ... lung, and other body sounds ... with the Littmann Model 3000., ... technology, up to 18 times ...
Medicine Products: